M. Campone, M. de Laurentiis, C. Zamagni, I. Kudryavcev, M. Agterof, U. Brown-Glaberman, M. Pálácova, S. Chatterjee, L. Menon-Singh, Jiwen Wu, K. Zhou, Miguel Martín
{"title":"摘要:Ribociclib +来曲唑治疗男性激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2−)晚期乳腺癌(ABC)患者:IIIb期supplement -1试验的亚组分析","authors":"M. Campone, M. de Laurentiis, C. Zamagni, I. Kudryavcev, M. Agterof, U. Brown-Glaberman, M. Pálácova, S. Chatterjee, L. Menon-Singh, Jiwen Wu, K. Zhou, Miguel Martín","doi":"10.1158/1538-7445.sabcs20-ps14-03","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract PS14-03: Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial\",\"authors\":\"M. Campone, M. de Laurentiis, C. Zamagni, I. Kudryavcev, M. Agterof, U. Brown-Glaberman, M. Pálácova, S. Chatterjee, L. Menon-Singh, Jiwen Wu, K. Zhou, Miguel Martín\",\"doi\":\"10.1158/1538-7445.sabcs20-ps14-03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20307,\"journal\":{\"name\":\"Poster Session Abstracts\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Session Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.sabcs20-ps14-03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Session Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.sabcs20-ps14-03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract PS14-03: Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial